

## RESPONSE TO REVIEWER 1:

We wish to express our appreciation to the Reviewer for the comments which have helped us improve our manuscript.

**Comment:** *This case report is well written structurally and stylistically. The disease subject of the study is a very rare condition and deserves to be published as a case report. I will only suggest one minor revision. Please additionally report your treatment plan for recurrent retroperitoneal lymph node after 24 months of follow-up.*

**Response:** We added following text in the section of **OUTCOME AND FOLLOW-UP** (p.8 line 24-p. 9 line 4):

“Due to the slow progression of the retroperitoneal lymph nodes, trastuzumab monoadministration was continued. When the retroperitoneal lymph nodes kept increase in size, nivolumab administration would be considered according to the gastric cancer chemotherapy regimens.”

Thank you once again for your valuable comments and suggestion. We are grateful for the time and energy you expended on our behalf.